A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema
Tekijät: Knobler Robert, Geroldinger-Simic Marija, Kreuter Alexander, Hunzelmann Nicolas, Moinzadeh Pia, Rongioletti Franco, Denton Christopher, Mouthon Luc, Cutolo Maurizio, Smith Vanessa, Gabrielli Armando, Bagot Martine, Olesen Anne B., Foeldvari Ivan, Jalili Ahmad, Kähäri Veli Matti, Karpati Sarolta, Kofoed Kristian, Olszewska Malgorzata, Panelius Jaana, Quaglino Pietro, Seneschal Julien, Sticherling Michael, Sunderkotter Cord, Tanew Adrian, Wolf Peter, Worm Margitta, Skrok Anna, Rudnicka Lidia, Krieg Thomas
Kustantaja: Wiley-Blackwell
Julkaisuvuosi: 2024
Journal: Journal of the European Academy of Dermatology and Venereology
Tietokannassa oleva lehden nimi: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Vuosikerta: 38
Numero: 7
Aloitussivu: 1281
Lopetussivu: 1299
ISSN: 0926-9959
eISSN: 1468-3083
DOI: https://doi.org/10.1111/jdv.19937
Verkko-osoite: https://doi.org/10.1111/jdv.19937
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/387694338
The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this consensus provides clinicians with an overview of the diagnosis and treatment of scleromyxoedema and scleroedema (of Buschke).
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
Editorial services was provided by Costello Medical, and funded by an independent medical writing grant provided by Mallinckrodt Pharmaceuticals. Mallinckrodt played no role in the development and review of the article, or approval to submit the article for publication. These tasks were solely the responsibility of the authors.
